

# Mitchell S Von Itzstein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7434573/publications.pdf>

Version: 2024-02-01

23  
papers

277  
citations

1163065

8  
h-index

996954

15  
g-index

24  
all docs

24  
docs citations

24  
times ranked

333  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis. <i>Clinical Chemistry</i> , 2020, 66, 779-793.   | 3.2 | 74        |
| 2  | Association between immune-related adverse event timing and treatment outcomes. <i>Oncolmmunology</i> , 2022, 11, 2017162.  | 4.6 | 33        |
| 3  | Type and case volume of health care facility influences survival and surgery selection in cases with early-stage non-small cell lung cancer. <i>Cancer</i> , 2019, 125, 4252-4259.  | 4.1 | 19        |
| 4  | Strategies to maximize influenza vaccine impact in older adults. <i>Vaccine</i> , 2018, 36, 5940-5948.  | 3.8 | 18        |
| 5  | Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud's-Like Phenomenon. <i>Oncologist</i> , 2020, 25, e753-e757.  | 3.7 | 17        |
| 6  | Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors. , 2021, 9, e002349.   |     | 16        |
| 7  | Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2169-2181.                 | 4.2 | 16        |
| 8  | Closing the gap: Contribution of surgical best practices to outcome differences between high- and low-volume centers for lung cancer resection. <i>Cancer Medicine</i> , 2020, 9, 4137-4147.                                  | 2.8 | 13        |
| 9  | Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?. <i>Oncologist</i> , 2020, 25, e1242-e1245.                       | 3.7 | 10        |
| 10 | Humoral and cellular correlates of a novel immune-related adverse event and its treatment. , 2021, 9, e003585.  |     | 10        |
| 11 | Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy. <i>Cancers</i> , 2022, 14, 1327.  | 3.7 | 9         |
| 12 | Severe destructive nasopharyngeal granulomatosis with polyangiitis with superimposed skull base <i>Pseudomonas aeruginosa</i> osteomyelitis. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-220135.                           | 0.5 | 8         |
| 13 | Increasing Numbers and Reported Adverse Events in Patients with Lung Cancer Undergoing Inpatient Lung Biopsies: A Population-Based Analysis. <i>Lung</i> , 2019, 197, 593-599.  | 3.3 | 8         |
| 14 | Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology. <i>Cancer</i> , 2020, 126, 1605-1613.   | 4.1 | 6         |
| 15 | Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality?. <i>PLoS ONE</i> , 2020, 15, e0231258. | 2.5 | 5         |
| 16 | Targeting TAM to Tame Pancreatic Cancer. <i>Targeted Oncology</i> , 2020, 15, 579-588.  | 3.6 | 4         |
| 17 | Accessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology?. <i>JCO Oncology Practice</i> , 2021, 17, e999-e1011.   | 2.9 | 3         |
| 18 | How lung cancer cells change identity. <i>ELife</i> , 2021, 10, .   | 6.0 | 3         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report. JTO Clinical and Research Reports, 2022, 3, 100291.                        | 1.1 | 3         |
| 20 | Contemporary Lung Cancer Screening and the Promise of Blood-Based Biomarkers. Cancer Research, 2021, 81, 3441-3443.   | 0.9 | 1         |
| 21 | Do mRNA profiles of lung adenocarcinomas provide information that will help individual patients?. EBioMedicine, 2020, 60, 103006.                                     | 6.1 | 0         |
| 22 | Immune toxicity and flow cytometry of circulating blood cells in cancer patients receiving immune therapy.. Journal of Clinical Oncology, 2020, 38, e15126-e15126.    | 1.6 | 0         |
| 23 | Correlating immune toxicity, blood cell counts, and overall survival in cancer patients receiving immune therapy.. Journal of Clinical Oncology, 2020, 38, 3043-3043. | 1.6 | 0         |